Drugmaker Dr Reddy’s Laboratories Ltd will launch its generic model of Merck’s antiviral COVID-19 capsule, molnupiravir, and worth it at 35 rupees per capsule, an organization spokesperson mentioned on Tuesday.
The general price for a affected person handled with a 5-day course of 40 capsules of the generic drug, to be bought beneath model title ‘Molflu’, will come as much as 1,400 rupees ($18.77). In comparability, the remedy with Merck’s capsule in america prices $700.
“Molflu is anticipated to be obtainable from early subsequent week in pharmacies all through (India) with specific concentrate on states with excessive caseload of COVID-19,” the corporate spokesperson mentioned.
India final week gave emergency use approval to molnupiravir together with two vaccines, because the nation braces for a doable spike in coronavirus instances as a result of quickly spreading Omicron variant.
India reported 37,379 new COVID-19 instances on Tuesday, its highest since early September.
With a view to show India into a producing hub, Merck has entered into licensing agreements with eight home drugmakers, together with Dr Reddy’s, to make and provide generic variations of molnupiravir to over 100 low- and middle- earnings nations.
A complete of 13 firms in India will make molnupiravir, the nation’s well being minister mentioned final week.
Governments world wide have been scrambling to purchase an identical however simpler antiviral remedy from Pfizer, whereas Merck’s capsule has confronted some setbacks after disappointing trial knowledge.
(This story has not been edited by BoardingFlight employees and is auto-generated from a syndicated feed.)